Andy Mead

Andy Mead currently serves as the Senior Director and Head of Toxicology at Grünenthal Group, where responsibilities include the development of a comprehensive non-clinical safety strategy and oversight of non-clinical safety studies. Prior to this role, Andy led drug abuse and substance use disorder initiatives at Sygnature Discovery and RenaSci, devised safety strategies at Sosei Heptares, and held a director position focusing on discovery safety at AstraZeneca. Previous experience includes leadership roles at Pfizer, specializing in CNS safety and abuse potential, and a notable tenure as a Senior Research Biologist at Merck. Academic credentials include a DPhil in Experimental Psychology and a BSc in Neuroscience, both from the University of Sussex.